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Activation of phosphoinositide 3-kinase (PI3K) and Akt (protein kinase B) is a common
response triggered by a range of membrane-bound receptors on many cell types. InT lym-
phocytes, the PI3K-Akt pathway promotes clonal expansion, differentiation, and survival of
effector cells and suppresses the generation of regulatory T cells. PI3K activation is tightly
controlled by signals through the T cell receptor (TCR) and the co-stimulatory receptor
CD28, however sustained and periodic signals from additional co-receptors are now being
recognized as critical contributors to the activation of this pathway. Accumulating evidence
suggests that many members of the Tumor Necrosis Factor receptor (TNFR) superfamily,
TNFR2 (TNFRSF1B), OX40 (TNFRSF4), 4-1BB (TNFRSF9), HVEM (TNFRSF14), and DR3
(TNFRSF25), that are constitutive or inducible on T cells, can directly or indirectly promote
activity in the PI3K-Akt pathway.We discuss recent data which suggests that ligation of one
TNFR family molecule organizes a signalosome, viaTNFR-associated factor (TRAF) adapter
proteins in T cell membrane lipid microdomains, that results in the subsequent accumu-
lation of highly concentrated depots of PI3K and Akt in close proximity to TCR signaling
units. We propose this may be a generalizable mechanism applicable to otherTNFR family
molecules that will result in a quantitative contribution of these signalosomes to enhancing
and sustaining PI3K and Akt activation triggered by theTCR. We also review data that other
TNFR molecules, such as CD40 (TNFRSF5), RANK (TNFRSF11A), FN14 (TNFRSF12A),TACI
(TNFRSF13B), BAFFR (TNFRSF13C), and NGFR (TNFRSF16), contribute to the activation
of this pathway in diverse cell types through a similar ability to recruit PI3K or Akt into their
signaling complexes.
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INTRODUCTION
The response of T lymphocytes to extrinsic stimuli has been known
for many years to involve activation of phosphoinositide 3-kinase
(PI3K) that results in a sustained rise in the lipid second messenger
phosphatidylinositol (3,4,5)-trisphosphate (PIP3 or PI(3,4,5)P3),
produced from phosphatidylinositol (4,5)-bisphosphate (PIP2 or
PI(4,5)P2), and translocation of a subset of proteins containing
pleckstrin homology (PH) domains to the plasma membrane,
such as Akt (protein kinase B) and phosphoinositide-dependent
kinase 1 (PDK1). Akt activity is regulated by the binding of PIP3
or phosphatidylinositol (3,4)-bisphosphate (PI(3,4)P2) to its PH
domain, and by phosphorylation on threonine 308 by PDK1 and
on serine 473 by the mammalian target of rapamycin complex
2 (mTORC2). Although PDK1 and mTORC2 may be central
to Akt function, they likely have activities unrelated to Akt. For
example, PDK1 also phosphorylates and activates other AGC pro-
tein kinases without binding to PIP3, such as 70 kDa ribosomal
protein S6 kinases (S6Ks), 90 kDa ribosomal protein S6 kinases
(RSKs), serum/glucocorticoid-regulated kinases (SGKs), and pro-
tein kinase Cs (PKCs) (Finlay and Cantrell, 2011). Importantly, the
signaling network regulated by PI3K and Akt plays an integral role
in promoting T cell activation, differentiation, and survival, and
also participates in suppressing the induction of Foxp3-expressing
regulatory T cells (Treg) that otherwise would limit the T cell
response (Fruman and Bismuth, 2009; Huang and Sauer, 2010;
Josefowicz et al., 2012; Okkenhaug, 2013). Activated Akt poten-
tially regulates many downstream molecules, directly or indirectly
through phosphorylation, that contribute to maximizing the T cell
response. These include blocking the activity of forkhead box O
(Foxo) transcription factors such as Foxo1 that promote differ-
entiation of inducible Treg, suppressing the activity or expression
of pro-apoptotic molecules such as Bad and Bim, antagonizing
the expression of cell cycle inhibitor proteins, and promoting
T cell functionality and survival by increasing glucose uptake
and glycolysis, and through augmenting IκB Kinase and NF-κB
activity.
The range of membrane receptors that participate in trigger-
ing this PI3K/Akt axis in T cells may have been underappreciated.
Recognition of antigen by the T cell receptor (TCR) in the context
of signaling from the co-stimulatory receptor CD28 has long been
known to promote PI3K activity. CD28 is constitutively expressed
on T cells, and engagement by B7 molecules (CD80 and CD86)
directly recruits the p85 regulatory subunit of PI3K (p85 PI3K)
through a pYMNM (phospho-Tyr-Met-Asn-Met) motif located
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in CD28’s cytoplasmic tail (Pages et al., 1994). The overall signal-
ing activity of CD28, including through the PI3K and Akt pathway,
participates in the initial activation and division of T cells in many
situations, although extensive studies have also suggested that the
interaction with p85 is dispensable for many functions of CD28
in naïve T cells (Fruman and Bismuth, 2009). As well as CD28
and related molecules like ICOS, many additional receptors on
T cells may contribute to PI3K and Akt activity. Sustained and
periodic signaling from these receptors over time is increasingly
being recognized as vital for continued T cell differentiation and
survival, further suppression of Treg development, the generation
of memory, and the reactivation of memory T cells. Members of
the tumor necrosis factor receptor (TNFR) superfamily constitute
many of these receptors (Croft, 2003, 2009; Watts, 2005; So et al.,
2006). Although all of the TNFR family members discussed in
this review are strong activators of NF-κB, and NF-κB certainly
plays a role in many of the functional consequences of trigger-
ing these receptors, increasing evidence suggests that their ability
to also target PI3K and Akt may be integral to their function.
In T cells, these receptors include TNFR2 (TNFRSF1B), OX40
(TNFRSF4), 4-1BB (TNFRSF9), HVEM (TNFRSF14), and DR3
(TNFRSF25), which are either constitutively expressed or induced
after activation (Figure 1). There are several other TNFR mol-
ecules that control T cell function, such as CD27 (TNFRSF7),
CD30 (TNFRSF8), and GITR (TNFRSF18), that have yet to be
described to promote activation of PI3K or Akt, however it is
highly likely that they also have the ability to target this path-
way (Figure 1). This review summarizes recent findings on the
potential importance of TNFR family signaling in stimulating the
PI3K-Akt pathway in T cells as well as in other cell types, and
FIGURE 1 |Tumor necrosis factor receptor family molecules that possibly
activate the PI3K-Akt pathway inT cells. Molecular interactions between
TNF receptor superfamily (TNFRSF) members and TNF ligand superfamily
(TNFSF) members: TNFR2 (TNFRSF1B) and TNF (TNFSF2) or LTα (TNFSF1);
OX40 (TNFRSF4) and OX40L (TNFSF4); CD27 (TNFRSF7) and CD70 (TNFSF7);
CD30 (TNFRSF8) and CD30L (TNFSF8); 4-1BB (TNFRSF9) and 4-1BBL
(TNFSF9); HVEM (TNFRSF14) and LIGHT (TNFSF14); GITR (TNFRSF18) and
GITRL (TNFSF18); DR3 (TNFRSF25) and TL1A (TNFSF15). Interactions
between TNFR-associated factors (TRAFs) and TNFRSF molecules are
indicated in the inner circle. CD27, CD30, and GITR have yet to be described
to promote activation of PI3K or Akt, but this is likely given their overlapping
TRAF-binding capacity.
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discusses the likely mechanism of how TNFR family molecules
organize signalosomes on the membrane to sustain lipid signaling.
The initial sections will present a brief overview of reported activ-
ities of TNFR family members on T cells that have been described
to augment PI3K or Akt activity. We will then discuss the potential
molecular connections that allow these molecules to link to PI3K
or Akt, and lastly review PI3K and Akt related activation by other
TNFR family members in non-T cells.
REGULATION OF T CELL CO-SIGNALING BY TNFRSF
MEMBERS: TNFR2, OX40, 4-1BB, HVEM, AND DR3
TNFR2 (TNFRSF1B)
TNFR2 is mainly expressed in cells of the immune system includ-
ing T cells. The ligand TNF (TNFSF2) is produced by activated
macrophages, T cells, and many other cell types, and exists as
a transmembrane trimer whose proteolysis also leads to a soluble
form. TNFR2 is more efficiently triggered by transmembrane TNF
than by soluble TNF (Grell et al., 1995; Faustman and Davis, 2010).
TNFR2 is constitutively expressed on T cells and increases its
expression after T cell activation. Interaction of TNF with TNFR2
is co-stimulatory to TCR-mediated T cell activation and effector T
cell differentiation (Kim and Teh, 2001, 2004; Aspalter et al., 2003;
Kim et al., 2006) and TNFR2-deficient T cells possess a defect in
survival during the early phase of clonal expansion that correlates
with a defect in survivin, Bcl-2, and Bcl-XL expression (Kim and
Teh, 2004; Kim et al., 2006). Importantly, TNFR2 was found to sus-
tain Akt activity in T cells stimulated through the TCR and CD28.
Given the described activities of PI3K-Akt in promoting expres-
sion of the aforementioned anti-apoptotic and cell cycle related
molecules in various cell types including T cells, this data sug-
gested that TNFR2 triggered Akt signaling may have participated
in regulating expansion and survival of these effector-type T cells
(Kim and Teh, 2004). The differentiation of effector T cells from
a naïve population is counter to the differentiation of regulatory
T cells (iTreg), and activation of PI3K and Akt has been shown
to block induction of Foxp3 and iTreg development (Haxhinasto
et al., 2008; Sauer et al., 2008). In line with this, neutralization
of TNF has also recently been found to enhance development of
iTreg cells (Zhang et al., 2013). TGF-β-induced Smad3 phospho-
rylation directs transcription of Foxp3 and formation of iTreg,
and phosphorylation of Akt through TNF-TNFR2 interaction was
described to facilitate Akt-Smad3 interaction and suppress Foxp3
expression, potentially explaining in part why TNF would block
iTreg differentiation (Zhang et al., 2013).
Substantiating that Akt is a general target of TNF signaling,
Akt phosphorylation has also been shown to be enhanced through
TNFR1 and/or TNFR2 in various cell types, such as HEK293 cells
(Ozes et al., 1999), HeLa cells (Ozes et al., 1999; Pastorino et al.,
1999), HepG2 cells (Reddy et al., 2000), U937 cells (Reddy et al.,
2000), endothelial cells (Zhang et al., 2003a), fibroblasts (Hanna
et al., 1999; Zhang et al., 2001), myocytes (Hiraoka et al., 2001),
cortical neurons (Marchetti et al., 2004), and hepatocytes (Osawa
et al., 2001).
OX40 (TNFRSF4)
OX40 is induced on activated T cells while its ligand, OX40L
(TNFSF4), is inducible on professional antigen-presenting cells
(APCs). OX40-OX40L interactions positively regulate conven-
tional T cell responses and can negatively affect Treg differenti-
ation (So et al., 2008; Croft et al., 2009; Croft, 2010; Ishii et al.,
2010). OX40 functions later than CD28, and potentially later than
TNFR2, providing signals to promote continued division and
survival, and hence clonal expansion of effector and memory T
cells (Gramaglia et al., 2000). OX40 signaling was shown to aug-
ment and sustain PI3K-Akt activity when antigen was presented
to T cells, again correlating with its ability to promote contin-
ued expression of molecules that control cell cycle progression as
well as anti-apoptotic Bcl-2 family members (Rogers et al., 2001;
Song et al., 2004, 2005). Importantly, a dominant-negative version
of Akt reproduced many of the defects associated with a lack of
OX40 expression, and introduction of a constitutively active ver-
sion of Akt into T cells that lacked OX40 almost fully reversed
the defect in clonal expansion and survival exhibited by these T
cells (Rogers et al., 2001; Song et al., 2004, 2005). OX40 signaling
also antagonizes the differentiation of Foxp3+ or IL-10+ iTreg
(Ito et al., 2006; So and Croft, 2007; Vu et al., 2007). No formal
proof has been provided that OX40 inhibition of Foxp3 and iTreg
development is mediated in part by Akt activation, but again this
is likely.
4-1BB (TNFRSF9)
4-1BB is another inducible molecule on activated T cells that can
be triggered by 4-1BBL (TNFSF9) expressed on activated APCs
(So et al., 2008; Snell et al., 2011; Vinay and Kwon, 2012). 4-1BB
ligation can again promote T cell clonal expansion, differentiation,
and expression of cytokines, and can enhance the survival of effec-
tor and memory T cells through upregulation of Bcl-XL. 4-1BB
signaling also has the ability to inhibit TGF-β-driven conversion
of naïve CD4+ T cells into iTreg either through direct activity or
indirectly via upregulation of IFNγ production (Madireddi et al.,
2012). 4-1BB was found to promote phosphorylation of Akt in T
cells, and proliferative responses mediated by 4-1BB were blocked
by a PI3K inhibitor, coincident with suppressing cyclin expression
and promoting the cell cycle regulatory molecules p27kip1 (Lee
et al., 2002, 2003). Some studies suggested that 4-1BB induced
the anti-apoptotic Bcl-2 family molecules, Bcl-2 and Bcl-xL, in
murine T cells in a PI3K-Akt independent manner (Lee et al.,
2002, 2003). However, suppression of apoptosis and induction of
c-FLIPshort and Bcl-XL by 4-1BB in human peripheral blood T cells
was blocked by targeting PI3K or Akt (Starck et al., 2005).
HVEM (TNFRSF14)
HVEM can interact with a number of different ligands, how-
ever its primary activating ligand in the TNF family is LIGHT
(TNFSF14). HVEM is widely expressed on many cell types, includ-
ing being constitutive on T cells. LIGHT in contrast is inducible
on T cells as well as certain APCs such as DC and B cells upon
activation (Steinberg et al., 2011; Ware and Sedy, 2011). Ligation
of HVEM by LIGHT provides stimulatory signals that addition-
ally can impact activation, differentiation, or survival of T cells. In
line with HVEM controlling Akt activation at later stages of T cell
responses, HVEM-deficient T cells were shown to display reduced
Akt activity at the peak of the effector response that correlated
with defective expression of Bcl-2 and reduced T cell survival.
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Furthermore, the defect in T cell survival was rescued by ectopic
expression of an active form of Akt (Soroosh et al., 2011).
Substantiating Akt as a downstream target of HVEM, the
ability of LIGHT to induce macrophage migration and vascular
smooth muscle cell proliferation also correlated with activation
of PI3K and Akt (Wei et al., 2006), and LIGHT was found to
promote PI3K-Akt phosphorylation in osteoclast precursor cells,
supporting osteoclast differentiation (Hemingway et al., 2013).
DR3 (TNFRSF25)
DR3 is constitutively expressed by T cells and is upregulated fol-
lowing T cell activation, while TL1A (TNFSF15), the ligand for
DR3, is induced in APCs (Meylan et al., 2011). Interaction of TL1A
with DR3 also provides costimulatory signals to T cells in concert
with antigen/TCR signaling and this can contribute to enhanced
production of pro-inflammatory cytokines, and increased clonal
expansion and differentiation of T cells. Although no studies have
been conducted as yet on conventional T cells, ligation of DR3 was
shown to promote Treg proliferation that was blocked by an Akt
inhibitor (Schreiber et al., 2010). Stimulation of DR3-expressing
human acute monocytic leukemia THP-1 cells with TL1A, or anti-
DR3 antibodies, also induced phosphorylation of Akt concomitant
with upregulation of expression of βig-h3, an extracellular matrix
protein. This was blocked by an inhibitor of PI3K and inhibitors
of PKC, suggesting that PKC activation by DR3 may be involved
in PI3K-Akt activation via this receptor in this cell type (Lee et al.,
2010). Lastly, E-selectin (CD62E) has been suggested to be an
alternate ligand for DR3, and E-selectin was found to activate
the PI3K-Akt pathway via DR3 in HT29 colon carcinoma cells
(Porquet et al., 2011).
TNF RECEPTOR OLIGOMERIZATION, MEMBRANE LIPID
MICRODOMAINS, AND THE T CELL TNFR SIGNALOSOME
Although the studies described above show that TNFR2, OX40,
4-1BB, HVEM, and DR3 can enhance PI3K and Akt activation
in T cells or other cell types, a primary question is whether
this is a direct activity, or indirect through modulating or
enhancing signaling through other non-TNFR molecules includ-
ing the TCR or CD28. Moreover, as these TNFR molecules do
not have obvious PI3K-binding motifs, similar to the pYMNM
motif of CD28, it is not clear how they would directly link to
PI3K or Akt or how the connection with the lipid mediators is
facilitated.
TNF family ligands share the TNF homology domain (THD),
which binds to cysteine-rich domains (CRDs) of the TNF family
receptors. TNF ligands are synthesized as either membrane-bound
or soluble trimeric proteins. Many biochemical and functional
studies show that the transmembrane ligands can robustly activate
receptors whereas the soluble trimeric ligands differ in their ability
to be activating molecules. Some TNFR molecules, such as TNFR1
and CD40, are thought to be pre-clustered at the cell surface in the
absence of their cognate TNF ligand (Chan,2007),which likely aids
their ability to respond to the soluble ligand. This is exemplified
by TNF, which is highly active in soluble form when recognizing
TNFR1. In contrast, studies of trimers of molecules such as OX40L
and 4-1BBL have suggested they do not have functional effects
when soluble, implying their receptors are not pre-assembled into
clusters. However, artificially generated oligomerized versions of
soluble trimeric ligands, including OX40L, 4-1BBL, and GITRL
work as highly efficient agonists in T cells and other cell types
(Haswell et al., 2001; Zhang, 2004; Stone et al., 2006; Muller et al.,
2008; Zhou et al., 2008; Wyzgol et al., 2009). Other variants on
this theme are molecules like APRIL whose soluble form can be
oligomerized naturally through interaction with polysaccharide
side chains of heparin sulfate proteoglycans, allowing effective sig-
nals through its receptors TACI or BCMA (Ingold et al., 2005;
Kimberley et al., 2009); or BAFF that also binds to TACI, and is
unable to activate this receptor as a single trimer, but can assem-
ble as an ordered structure comprising 20 trimers (60-mer) and
then gains the ability to be a strong TACI agonist (Liu et al., 2002;
Bossen et al., 2008). In sum, these results suggest that oligomeriza-
tion of most TNFR molecules, beyond the basic trimer complex
that would be formed after ligation of a single trimeric ligand, is
a prerequisite for efficient recruitment and activation of signaling
moieties.
All TNFR family molecules also promote intracellular kinase
activation at least in part through adaptor proteins called TNFR-
associated factors (TRAFs). For example, TNFR2 has the potential
ability to recruit and/or directly bind TRAFs 1 and 2 (Rothe et al.,
1994); OX40: TRAFs 1, 2, 3, and 5 (Kawamata et al., 1998); 4-
1BB: TRAFs 1, 2, and 3 (Jang et al., 1998); HVEM: TRAFs 1, 2, 3,
and 5 (Marsters et al., 1997); and DR3: TRAF2 (Chinnaiyan et al.,
1996). TRAF proteins already can exist as trimers in the cytosol
before binding to the cytoplasmic tails of TNF receptors (Park
et al., 1999), suggesting that oligomerization of the receptors will
then additionally result in oligomerized scaffolds of at least one,
but more likely multiple, TRAF molecules.
Another facet that might be important to the ability of
TNFR family molecules to link to PI3K and Akt directly is
the regulated movement of TNFR oligomers into detergent-
insoluble cholesterol- and sphingolipid-rich plasma membrane
microdomains (DIM or lipid rafts). Here the spatiotemporal
regulation of protein–protein interactions and dynamic protein
networks may orchestrate to allow any biological outcome (Dyk-
stra et al., 2003; Viola and Gupta, 2007). DIM are estimated as
<20 nm diameter in a living cell (Eggeling et al., 2009), indicat-
ing that molecules that translocate into DIM are likely condensed
into a small area. Although not investigated for many TNFR mol-
ecules to date, particularly in T cells, several members of the
family have been visualized to concentrate in DIM after stimu-
lation by their ligands including OX40 (So et al., 2011a,b) and
4-1BB (Nam et al., 2005). Therefore, translocation into lipid-
rich microdomains might be a common and important feature of
the TNFR family. Moreover, TRAF2 can interact with Filamin-A,
which functions as a scaffold for DIM formation (Leonardi et al.,
2000; Arron et al., 2002), and with Caveolin-1, which is a com-
ponent of DIM (Feng et al., 2001), suggesting that recruitment of
this molecule might promote or maintain localization of TNFR
molecules in these lipid-rich areas. TRAF2 binding is shared by all
TNFR family molecules that have been described to co-stimulate
T cells (Figure 1), including those shown to date to promote PI3K
and Akt activation (see above), implying TRAF2 may be a criti-
cal link to PI3K and/or Akt. Perhaps of equal significance, PIP2
is enriched and constitutively associated with DIM, and at least
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in T cells, a proportion of total cellular PI3K and PDK1 are con-
stitutively associated with detergent-insoluble fractions (Pike and
Casey, 1996; Dykstra et al., 2003; So et al., 2011a). Therefore, it
is reasonable to suggest that these lipid-rich microdomains are
likely to play a critical role in triggering PI3K-Akt signaling by
facilitating the localization of oligomerized TNFR and TRAF mol-
ecules with PI3K, PIP2, and PDK1 (Lasserre et al., 2008). This
would enhance the likelihood of PIP3 production, and membrane
recruitment and phosphorylation of Akt, assuming PI3K can be
activated.
Only studies of one molecule to date have shown a direct link
of a TNFR family molecule to PI3K and Akt in T cells. However,
there is strong rationale that the findings will be generalizable.
We clearly demonstrated in several studies that OX40 signaling
strongly synergizes with antigen signals to augment Akt activ-
ity in recently activated or effector T cells (Song et al., 2004; So
et al., 2011a,b). After interaction of OX40 with transmembrane
OX40L, OX40 moved into DIM and immunoprecipitation exper-
iments revealed that it organized a signalosome containing many
molecules including TRAF2, the IKK complex, and PKCθ and the
CARMA1-BCL10-MALT1 complex, that regulate NF-κB1 activa-
tion, and also including p85 PI3K and Akt (So et al., 2011a,b).
The formation of this complete OX40 signalosome in T cells was
dependent on TRAF2 and on translocation of OX40 into DIM,
but independent of antigen/TCR stimulation (So et al., 2011a,b).
Moreover, in the absence of TRAF2 or by disrupting DIM, OX40
could not complex with either PI3K or Akt. Interestingly, OX40
was unable to induce significant cellular phosphorylation of PI3K,
PIP3 accumulation, or Akt activation, unless antigen was presented
to the T cells, even though antigen/TCR signaling had no obvious
impact on recruitment of PI3K or Akt to the OX40 signalosome.
The explanation for this was not clear, but we only found a moder-
ate amount of PDK1 associated with the OX40 complex suggesting
that this might in part contribute to the inability of OX40 ligation
in isolation to lead to phosphorylation of Akt, and why antigen
recognition was essential. However, more recent data have shown
that OX40 associates with an E3 ligase that appears to limit its
ability to activate Akt in T cells (Croft, unpublished). This then
suggests that OX40 does possess the capacity to activate Akt inde-
pendently of other receptors, but regulatory elements may keep
this ability in check in T cells providing control over this aspect
of OX40 biology to the TCR. Importantly, these data then imply
that OX40 functions in T cells by quantitatively enhancing the
amount of PI3K and Akt that is available to be activated in the
lipid-rich microdomain environment. We hypothesize that the
higher ordered oligomerized TNFR-ligand modules that are orga-
nized in DIM of T cells essentially offer functional hot spots of
concentrated PI3K and Akt in the vicinity of the TCR/CD28 sig-
nalosome (Figure 2). These data also highlight that TRAF adaptors
are likely to play critical roles in linking the TNFR family to PI3K
and Akt in T cells. Our studies show that TRAF2 is important
for OX40 to recruit both PI3K and Akt into its signaling com-
plex, but whether TRAF2 directly binds one or both molecules
is not yet clear. Other TRAFs, particularly TRAF6, may be also
critical as described below in non-T cells, although how much
this might vary from a T cell to another cell type is also not
clear.
REGULATION OF PI3K AND AKT BY TNFRSF MEMBERS IN
NON-T CELLS: CD40, RANK, FN14, TACI/BAFFR, AND NGFR
CD40 (TNFRSF5)
Signaling through CD40 after ligation by CD40L (TNFSF5) is
important for promoting the activation, division, and maturation
of APCs, and isotype switching of B cells (Graham et al., 2010;
Gommerman and Summers deLuca, 2011). CD40 can directly
bind to TRAFs 1, 2, 3, 5, and 6 (Pullen et al., 1998) and CD40
engagement leads minimally to translocation of CD40, TRAF2,
TRAF3, and TRAF6 into DIM where CD40 activates downstream
signaling cascades (Hostager et al., 2000; Vidalain et al., 2000;
Arron et al., 2001). Cross-linking CD40 has been found to acti-
vate PI3K in the Daudi human B lymphoblastoid line (Ren et al.,
1994), and promote Akt phosphorylation, downregulation of
p27kip1, and upregulation of Bcl-XL, in primary murine B cells
that was blocked by a PI3K inhibitor (Andjelic et al., 2000).
CD40-induced proliferation and survival of B cells deficient in
a negative regulatory adaptor molecule was also suppressed by
introduction of dominant-negative Akt (Aiba et al., 2006). After
triggering CD40 on murine bone marrow-derived DCs, p85 PI3K
was furthermore found to be recruited to CD40 correlating with
enhanced Akt activation (Arron et al., 2001). Similarly, CD40L
induced Akt phosphorylation and survival in human monocyte-
derived DCs that was blocked with a PI3K inhibitor (Yu et al.,
2004). In other cells, stimulation of CD40 on human microvas-
cular endothelial cells also induced PI3K and Akt phosphoryla-
tion, concomitant with an increase in cell survival and prolifer-
ation, and these functional activities were suppressed by PI3K
inhibitors and a dominant-negative version of Akt (Deregibus
et al., 2003).
Although the adaptors required for CD40 to connect to PI3K
and Akt have not been investigated in every situation, several pieces
of evidence suggest TRAF6 and/or TRAF2 are crucial. For exam-
ple, CD40 was shown to block apoptosis induced by the Fas death
receptor in a PI3K and Akt dependent manner, and this was abro-
gated in B cells that were deficient in TRAF6 (Benson et al., 2006).
A CD40 signalosome containing TRAF2, TRAF6, and p85 PI3K
was also visualized in endothelial cells (Deregibus et al., 2003) and
a signalosome of TRAF6 and PI3K in DCs (Arron et al., 2001).
Lastly, fibroblasts lacking TRAF2 or TRAF6 displayed impaired Akt
phosphorylation that was triggered by CD40 engagement (Davies
et al., 2005).
RANK (TNFRSF11A)
RANK interactions with RANKL (TNFSF11) regulate bone
remodeling, lymph node formation, establishment of the thymic
microenvironment, and mammary gland development during
pregnancy (Leibbrandt and Penninger, 2008). RANK has the
potential to recruit TRAFs 1, 2, 3, 5, and 6 (Wong et al., 1998;
Darnay et al., 1999) and triggering of RANK with RANKL has
been shown to promote activation of the PI3K-Akt pathway in
osteoclasts and DCs. Similar to CD40, RANK was visualized to
induce a signalosome containing TRAF6 and p85 PI3K in these
cell types. PP1, an inhibitor for Src family kinases, inhibited Akt
phosphorylation mediated by RANK, indicting that c-Src is an
upstream regulator of PI3K. In accordance, the kinase activity of
c-Src was upregulated in the RANK signalosome and RANK was
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FIGURE 2 | Model of synergy betweenTCR/CD28 andTNFR
signalosomes for activation of the PI3K-Akt pathway inT cells. T cells are
activated firstly by recognition of antigen by the T cell receptor (TCR)/CD3
complex when it is displayed by the major histocompatibility complex (MHC)
on antigen-presenting cells (APCs). The second co-stimulatory signal is
delivered through CD28 by interaction with its ligands CD80 and/or CD86.
These combined signals can activate phosphoinositide 3-kinase (PI3K), which
leads to conversion of PIP2 into PIP3 at the plasma membrane. The pleckstrin
homology (PH) domain containing proteins, Akt (protein kinase B) and
phosphoinositide-dependent kinase 1 (PDK1), are recruited to the membrane
PIP3, and then Akt is phosphorylated by PDK1 and by the mammalian target
of rapamycin complex 2 (mTORC2). This promotes translocation of Akt from
membrane to cytosol, thereby allowing regulation of downstream pathways
through phosphorylation of target molecules, such as glycogen synthase
kinase 3β (GSK3β), forkhead box O (Foxo), and IκB kinase (IKK). Akt
phosphorylates and inactivates two negative regulators of mTORC1, tuberous
sclerosis complex 2 (TSC2) and proline-rich Akt substrate of 40 kDa (PRAS40),
which results in activation of mTORC1. Akt contributes to NF-κB activation
through phosphorylation of IKK and interaction with protein kinase C θ (PKCθ)
or caspase-recruitment domain (CARD)-membrane-associated guanylate
kinase (MAGUK) protein 1 (CARMA1). After recognition of trimeric TNF ligand
superfamily (TNFSF) molecules on APCs, TNF receptor superfamily (TNFRSF)
molecules on T cells are trimerized and oligomerized and recruit trimeric
TNFR-associated factors (TRAFs) to their cytoplasmic TRAF-binding motifs.
The TNFSF-TNFRSF complex then translocates into detergent-insoluble
membrane lipid microdomains (DIM). The TNFRSF-TRAF superclusters recruit
and allow the efficient accumulation of PI3K and Akt in concentrated depots
in close proximity to the TCR/CD28 signalosome, which results in a
quantitative contribution of TNFR signalosomes to enhancing and sustaining
PI3K and Akt activation triggered by the TCR/CD28 signalosome. The TNFR
signalosomes also can promote activation of NF-κB irrespective of TCR/CD28
signaling. Red lines show activating signals, blue lines show inhibitory signals.
found unable to activate Akt without the enzymatic activity of
c-Src (Wong et al., 1999; Arron et al., 2001; Xing et al., 2001).
TRAF6 again may be critical for the ability of RANK to tar-
get the PI3K-Akt pathway, and certain elements might also limit
Akt activation. Upon stimulation of RANK in the RAW264.7
monocyte/macrophage cell line, phosphorylation of PI3K and
Akt was upregulated and this was further amplified by introduc-
tion of dominant-negative SHP-1. TRAF6 was found to interact
with RANK and SHP-1, and SHP-1 antagonized the association
between RANK and TRAF6 (Zhang et al., 2003b). Similar to other
TNFR molecules, RANK may also function in the context of DIM.
After engagement by RANKL in osteoclasts, TRAF6 was shown
to translocate into DIM where c-Src is constitutively resident,
and disruption of DIM reduced Akt activation and concomitantly
blocked osteoclast differentiation, survival, and bone resorption
activity (Ha et al., 2003).
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FN14 (TNFRSF12A)
FN14 is another TNFR molecule. It is expressed on epithelial cells,
endothelial cells, and other non-hematopoietic cells and engages
TWEAK (TNFSF12) and promotes a number of differentiation
activities depending on the cell type. Stimulation of FN14 on
mouse osteoblastic MC3T3-E1 cells induced Akt phosphorylation
and RANTES production in a PI3K-dependent manner (Ando
et al., 2006). TWEAK also promoted expression of ICAM-1 and
VCAM-1 on human gingival fibroblasts that was blocked with an
inhibitor of PI3K (Hosokawa et al., 2006), and Akt phosphoryla-
tion and matrix metalloprotease-9 (MMP-9) expression in mouse
C2C12 myotubes was suppressed by targeting PI3K or introducing
a dominant-negative version of Akt (Kumar et al., 2009). Simi-
lar results were also reported with TWEAK activation of FN14
on: renal tubular epithelium cells where PI3K inhibitors pre-
vented upregulation of cyclin D1 and cell proliferation (Sanz et al.,
2009); cardiomyocytes where FN14-mediated proliferation was
also blocked by interfering with PI3K activity (Novoyatleva et al.,
2010); and human gingival fibroblasts where the PI3K-Akt path-
way contributed to induction of CCL20 (Hosokawa et al., 2012).
FN14 has the potential to directly recruit and bind TRAFs 1, 2, 3,
and 5 (Brown et al., 2003) but no studies to date have attempted to
link a specific TRAF to the ability of FN14 to phosphorylate and
activate PI3K or Akt.
TACI (TNFRSF13B)/BAFFR (TNFRSF13C)/BCMA (TNFRSF17)
TACI, BAFFR, and BCMA are mainly expressed on B cells and
play critical roles in survival of B cells at distinct stages of develop-
ment by engaging APRIL (TNFSF13) and/or BAFF (TNFSF13B)
(Rickert et al., 2011). BAFFR can activate the PI3K-Akt pathway
in mature B cells (Patke et al., 2006; Otipoby et al., 2008; Wood-
land et al., 2008) and BAFF-mediated proliferative and survival
responses were defective in B cells lacking p110δ PI3K (Henley
et al., 2008). PKCβ was found to interact and directly phos-
phorylate Akt on serine 473 after ligation of BAFFR, with Akt
phosphorylation being greatly reduced in PKCβ-deficient B cells
(Patke et al., 2006). Follicular lymphoma B cells were additionally
found to respond to APRIL-TACI stimulation by phosphorylating
p85 PI3K, Akt, mTOR, 4E-BP1, and p70S6K, and PI3K inhibitors
blocked these APRIL-induced activities and cellular proliferation
(Gupta et al., 2009).
Stimulation of human myeloma cells expressing TACI, BAFFR,
and BCMA with BAFF or APRIL has also been shown to acti-
vate the PI3K-Akt pathway concomitant with protection against
apoptosis (Moreaux et al., 2004); and lastly human adipose-
derived stem cells additionally phosphorylated Akt after exposure
to APRIL or BAFF (Zonca et al., 2012). Similar to other TNFR fam-
ily members, TACI, BAFFR, and BCMA may directly recruit and
bind TRAFs 2, 5, and 6 (Xia et al., 2000), TRAFs 2 and 3 (Xu and
Shu, 2002), and TRAFs 1, 2, 3, 5, and 6 (Hatzoglou et al., 2000; Shu
and Johnson, 2000), respectively, suggesting that TRAF2 and/or 6
may again mediate PI3K-Akt signaling, although no studies have
addressed this as yet.
NGFR (TNFRSF16, p75NTR)
Lastly, NGFR that is mainly expressed on neurons and glia during
development of the central nervous system, and is induced after
many types of nervous system injury, also appears to utilize PI3K
and Akt for certain activities. NGFR only binds neurotrophins
[nerve growth factor (NGF); brain-derived neurotrophic factor
(BNDF); and neurotrophin-3 and -4 (NT-3 and -4)]. NGFR may
primarily work as a co-receptor and cooperates with the Trk recep-
tor tyrosine kinase family (Trk-A, -B, and -C), Sortilin-family
receptors, and Nogo receptor/Lingo-1 (Ibanez and Simi, 2012).
Many studies (e.g., refs Soltoff et al., 1992; Yao and Cooper, 1995;
Jackson et al., 1996; Vaillant et al., 1999; Takano et al., 2000) have
shown that NGF activates PI3K and induces PIP3 production, and
that the Akt pathway works as a key regulator of neurotrophin-
induced neuronal survival. NGFR signaling is initiated in caveolae,
which are a special type of DIM and serve as signaling platforms
(Bilderback et al., 1999; Huang et al., 1999), but the contribution
of individual TRAF molecules to activation of PI3K and Akt has
not yet been reported. NGFR can directly bind TRAFs 2 and 6
(Khursigara et al., 1999; Ye et al., 1999), and TRAF6 recruitment
has been suggested to be essential for signal transduction activity
(Vilar et al., 2009), again implying this receptor may connect to the
PI3K-Akt pathway via similar TRAF adaptors as other members
of the TNFR family.
CONCLUSION
In conclusion, many stimulatory TNFR family members have
been reported to augment PI3K and Akt activation in diverse
cell types, suggesting that this pathway can be a major contrib-
utor to the functional effects mediated by these molecules. After
interaction with their transmembrane, and in some cases soluble,
TNF family ligands, TNFR molecules oligomerize and organize
signalosomes in membrane lipid microdomains. The cytoplasmic
domain of TNFR family members does not have the consen-
sus motif that can directly bind PI3K. Rather, TNFR molecules
bind to overlapping but distinct subsets of TRAF adaptor pro-
teins, and these adaptors initiate many of the signals delivered
by the receptors. Increasing evidence suggests that TRAF2 and/or
TRAF6 are required for recruitment of PI3K or Akt into TNFR
signalosomes, but whether these TRAF molecules directly bind to
PI3K or Akt is not clear. In overexpression studies, and in MEFs
stimulated with IGF-1 or IL-1, TRAF6 was precipitated with Akt,
and furthermore TRAF6 induced K63-linked ubiquitination and
membrane localization of Akt (Yang et al., 2009). Thus it is pos-
sible that this is also a primary activity when TRAF6 is recruited
to a TNFR molecule. However, not all TNFR family members that
have been reported to promote PI3K and Akt activation appear
to bind or recruit TRAF6, but they may all interact with TRAF2.
This implies that TRAF2 could be the crucial adaptor in some
cases, but whether TRAF2 possesses the same activity as TRAF6
in being able to complex with, and ubiquitinate, Akt is presently
unknown.
In T cells, TNFR family molecules are crucial for clonal expan-
sion and survival, and for the generation of T cell memory, and
increasing evidence suggests these functional effects are in part
mediated by enhancing antigen-initiated PI3K and Akt activity.
Some TNFR family molecules in non-T cells appear to have the
capacity to activate PI3K and Akt without signaling from other
receptors, suggesting they may directly phosphorylate PI3K and/or
recruit other kinases that can perform this function, and they
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may also recruit kinases such as PDK1 that phosphorylate Akt.
In contrast, most evidence suggests that in T cells the ability of
TNFR molecules to promote phosphorylation of PI3K and Akt is
restricted unless the TCR recognizes antigen. This makes sense as
T cells are governed by many checkpoints that limit their response
in an attempt to control autoreactivity. Thus, it is likely that the
higher-order TNFR-TRAF superclusters induced within lipid-rich
microdomains of T cells then allow the efficient accumulation of
PI3K and Akt in concentrated depots in close proximity to the
TCR signalosome, and the function of this would be to either
relieve a molecular checkpoint that limits Akt phosphorylation,
or would be to simply provide more molecules of Akt avail-
able to the TCR. Further work in this area is required to fully
understand the nature of TNFR signalosomes and how they may
differ from molecule to molecule and in T cells versus other cell
types.
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